Researchers found that a new blood test may help doctors predict how well patients will respond to popular weight-loss medications like Ozempic and Wegovy. This advancement comes from a California-based company called Hepta, which has identified specific blood markers that indicate a patient’s biological predisposition to respond to these drugs. The findings were presented at Digestive Disease Week 2026, suggesting a shift from trial-and-error prescribing to a more personalized, biology-guided approach.

For people looking to lose weight and improve their health, this could mean more effective treatment options. The study focused on overweight and obese individuals with nonalcoholic fatty liver disease, analyzing blood samples before and after treatment with the GLP-1 drug semaglutide. Those who responded to the medication lost at least 10% of their body weight over a year, while changes in their blood markers indicated how the drug was affecting them. This kind of personalized insight could lead to better outcomes for individuals seeking to manage their weight and related health issues.

The research is still in the early stages, as it involved a real-world study rather than a large clinical trial. Hepta’s findings are promising but not yet proven on a broad scale. The company is planning further studies to explore whether its blood test can predict responses to other medications as well. For now, the test offers hope for a more tailored approach to weight loss treatments, moving away from guesswork in prescribing these medications.

Source: fiercebiotech.com